{"id":"37955905654-37","name":"CELGENE","registrationDate":"2011-04-14T10:05:22.699+01:00","category":2,"subCategory":3,"legal":"Corporation - publicly traded","web":"http://www.celgene.com/","country":"United states","headAddress":"Morris Avenue, 86","headCity":"Summit","headPostCode":"NJ07901","headPhone":"(01)90 86 73 90 00","boss":"Tuomo Patsi","bossTitle":"Mr","bossPosition":"President, European and International Operations","membersCount":5,"membersFTE":"2.5","membership":"Celgene is a member of following organizations in Brussels:&#xd;\nEuropean Federation of Pharmaceutical Industries and Associations (EFPIA)&#xd;\nEuropean Confederation of Pharmaceutical Entrepreneurs (EUCOPE)&#xd;\nAmerican Chamber of Commerce to the European Union (AmCham EU)","memberOrga":"","goal":"Celgene is building a preeminent global biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for patients with cancer, immune-inflammatory, and other unmet medical needs.","acronym":"","interests":"Competition, Consumer Affairs, Employment and Social Affairs, Enterprise, General and Institutional Affairs, Internal Market, Public Health, Research and Technology, Taxation, Trade","euInitiatives":"Celgene works with European institutions to raise awareness of diseases with a high unmet medical need - such as rare diseases, rare cancers and immune and inflammatory diseases - to drive greater focus on patients with these underserved conditions. We seek cooperation in policy developments that improve regulatory processes for pharmaceuticals and ensure the right environment for research and industry in Europe. We foster debates around improved and equal access to innovative medicines for patients through open dialogues with European policy-makers.&#xd;<br />&#xd;<br />We therefore monitor EU initiatives related to the registration and evaluation of medicines as well as the follow-up of the Council conclusions of June 2016, EU Commission's activities on rare diseases, the current debate on access to medicines, and intellectual property issues.","lastUp":"2017-04-03T13:41:16.055+01:00","customers":"","costAbsolu":"","costRange":"400000-499999","turnoverAbsolu":0,"turnoverRange":""}